Click here to read the latest top Canadian cannabis stocks list.

The marijuana stock market has held investors’ attention during 2019, even as sentiment adjusts and expectations for the industry change.

Companies have faced a volatile market this year, with a now recognized pullback dragging the space down. But while the overall sector has experienced a downturn, investors have still found opportunities for gains in the marijuana stock universe.

Read on to view the top cannabis gainers so far this year on the CSE, TSXV and TSX. All stats were current as of September 30, 2019; CSE and TSXV stocks listed had market caps between C$10 million and C$500 million at that time, and TSX stocks listed had market caps between C$1 billion and C$15 billion.

CSE top cannabis stocks

1. Captiva Verde Land (CSE:PWR)

This relative newcomer to the marijuana public sector started trading on the CSE in October 2018. It is a real estate company with investments in various areas, including cannabis operations.

While Captiva Verde Land did not have a quarter full of announcements, it did complete an acquisition of facilities that will help support the outdoor growing operations of its marijuana grower subsidiary Solargram Farms. The firm has indicated it is expecting a first harvest sometime in 2020 for both its indoor and outdoor cannabis product.

Shares of Captiva have risen 200 percent over a year-to-date period to reach a price of C$0.24.

2. Benchmark Botanics (CSE:BBT)

This cannabis company has operations in Canada and in Europe. Thank to its subsidiary Potanicals Green Growers, the firm holds a license for marijuana production in Peachland, British Columbia.

During the quarter, the company completed a new partnership with Zhejiang Yatai Pharmaceutical (SZSE:002370), a Chinese drugmaker. This partnership will produce a joint venture to “explore opportunities, subject to compliance with Canadian Cannabis Act and related Regulations, to cultivate, manufacture, process, and market high content cannabidiol cannabis products.”

Additionally, shares of the company were added to the Horizons Emerging Marijuana Growers Index ETF (NEO:HMJR) during the quarter, offering increased exposure.

Benchmark Botnics’ shares have risen 104.35 percent in value this year for a price of C$0.47.

3. Citation Growth (CSE:CGRO)

Formerly known as Liht Cannabis, this company manages marijuana assets in Nevada, Washington, California and British Columbia. During the third quarter, the firm conducted a critical merger with ACC Group of Companies, a Nevada cannabis cultivation operation.

“The acquisition of ACC provides the fuel required to accelerate Citation’s movement to large-scale cannabis cultivation and production,” Rahim Mohamed, president of Citation Growth, said in a statement. As part of the transaction, the public firm issued 35 million shares.

Citation faced a roadblock in October due to an error in the filing of its financial statement for the year ended on March 31, 2019. Three key amendments were made to the statement.

So far in 2019, shares of this firm have increased in value by 63.24 percent to rest at C$0.25.

TSXV top cannabis stocks

1. SugarBud Craft Growers (TSXV:SUGR)

During Q3, SugarBud Craft Growers obtained its cultivation, processing and medical sales licenses from Health Canada. This officially kicked off operations for the firm out of its facility in Stavely, Alberta.

“As a premium product provider, focused on quality, product leadership and customer satisfaction, we believe that the heart and soul of everything we do starts with what we grow,” John Kondrosky, CEO of the firm, said in a statement.

Due to the pullback in the cannabis market, the entire Canadian marijuana space saw a sharp decline in performance during the third quarter.

SugarBud Craft Growers was no stranger to this effect — although its share price is up only 12.5 percent to C$0.08, the company is the TSXV’s top-performing cannabis stock so far this year.

2. 48North (TSXV:NRTH)

This novelty cannabis grower had a busy summer with a collection of developments, including an update on its outdoor growing facility, a US-based acquisition and an executive management shakeup.

48North issued its fiscal 2019 results in September, reporting net revenues of C$4.8 million. During the period, the company raised close to C$50 million for a cash position of C$52.7 million. However, the firm posted a net loss for the year of C$8.1 million. 

So far this year, the company has seen an increase in value of 1.64 percent for a price of C$0.62.

TSX top cannabis stocks

1. Alcanna (TSX:CLIQ)

Alcanna manages the retail operations of Nova Cannabis and is associated with Canadian producer Aurora Cannabis (TSX:ACB,NYSE:ACB).

As part of its most recent quarterly update to investors, Alcanna said that a Nova Cannabis shop in Toronto, Ontario, has quickly gained the most volume of all its stores in the country. This store averages C$450,000 per week. Alcanna manages nine stores across Canada: eight in Alberta and one in Ontario.

Shares of Alcanna have grown by 20.9 percent so far this year, resulting in a price of C$5.20.

2. Charlotte’s Web Holdings (TSX:CWEB)

This hemp-derived cannabidiol (CBD) manufacturer has continued its path in the US by offering novelty products in high demand across the country.

This past quarter, the firm reported steady operational growth during Q2. During a call with investors, Deanie Elsner, CEO of Charlotte’s Web Holdings, said the firm is cautiously optimistic about the national conversation around CBD regulation with the US Food and Drug Administration (FDA).

“While the farm bill unlocked the door for category availability, the FDA now has the opportunity to expand availability of hemp CBD products across more distribution points to benefit more consumers,” Elsner said during the call.

Over a year-to-date period, shares of the CBD producer have risen 2.63 percent for a price of C$18.35.


This Canadian marijuana producer joined a few of its peers by securing a listing on the New York Stock Exchange (NYSE) in July.

“We are extremely pleased to list on the NYSE and believe it reaffirms HEXO’s strong track-record for exceptional corporate governance and is further proof that we are a valuable cannabis industry partner for Fortune 500 companies,” CEO and Co-founder Sebastien St-Louis said in a statement.

Also in Q3, HEXO was able to increase the availability of its products in the Canadian market. In Alberta, the firm started selling its cannabis Elixir oral sprays, while in Ontario HEXO secured 18 new product variety listings with the provincial distributor, the Ontario Cannabis Store.

Shares of HEXO have scaled up 0.38 percent in value, resulting in a price per share of C$5.23.


Want more details? Check out these articles for more INNdepth coverage.

Want an overview of investing in cannabis stocks? Check Investing in the Cannabis Industry

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less